These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19259302)

  • 1. Responding to the rising incidence of hepatocellular carcinoma with targeted therapy.
    Choo SP; Venook AP
    Gastrointest Cancer Res; 2008 Mar; 2(2):96-7. PubMed ID: 19259302
    [No Abstract]   [Full Text] [Related]  

  • 2. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States.
    Kulkarni K; Barcak E; El-Serag H; Goodgame R
    Aliment Pharmacol Ther; 2004 Aug; 20(4):445-50. PubMed ID: 15298639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean?
    Shaw JJ; Shah SA
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):365-70. PubMed ID: 21651354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rising incidence of hepatocellular carcinoma in the United States.
    El-Serag HB; Mason AC
    N Engl J Med; 1999 Mar; 340(10):745-50. PubMed ID: 10072408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Hepatocellular Cancer: the Current State of Future Research.
    Connell LC; Harding JJ; Abou-Alfa GK
    Curr Treat Options Oncol; 2016 Aug; 17(8):43. PubMed ID: 27344158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003.
    Ahmed F; Perz JF; Kwong S; Jamison PM; Friedman C; Bell BP
    Prev Chronic Dis; 2008 Jul; 5(3):A74. PubMed ID: 18558024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for immunotherapy in hepatocellular carcinoma?
    Zerbini A; Pilli M; Ferrari C; Missale G
    Dig Liver Dis; 2006 Apr; 38(4):221-5. PubMed ID: 16461021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current staging of hepatocellular carcinoma: imaging implications.
    Bhosale P; Szklaruk J; Silverman PM
    Cancer Imaging; 2006 Jul; 6(1):83-94. PubMed ID: 16829469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.
    Mody K; Abou-Alfa GK
    Curr Treat Options Oncol; 2019 Jan; 20(2):3. PubMed ID: 30635732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].
    Zhang DZ; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):834-837. PubMed ID: 31941237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of the nuclear transport system in hepatocellular carcinoma - New basis for therapeutic strategies.
    Beck M; Schirmacher P; Singer S
    J Hepatol; 2017 Nov; 67(5):1051-1061. PubMed ID: 28673770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rising incidence of hepatocellular carcinoma.
    Kaczynski J; Odén A
    N Engl J Med; 1999 Aug; 341(6):451; author reply 452. PubMed ID: 10438267
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
    Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
    Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R; Byrne MT; Tan A; Aucejo F
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis.
    Gao X; Yang HI; Trinh H; Jeong D; Li J; Zhang J; Le A; Hoang J; Nguyen P; Henry L; Nguyen MH
    Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1207-1211. PubMed ID: 32129773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin.
    Ampuero J; Romero-Gomez M
    World J Hepatol; 2015 May; 7(8):1105-11. PubMed ID: 26052399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving epidemiology of hepatocellular carcinoma: a global perspective.
    Wallace MC; Preen D; Jeffrey GP; Adams LA
    Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):765-79. PubMed ID: 25827821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for developing hepatocellular carcinoma in Egypt.
    Omar A; Abou-Alfa GK; Khairy A; Omar H
    Chin Clin Oncol; 2013 Dec; 2(4):43. PubMed ID: 25841922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of interferon alpha 2a on incidence of hepatocellular carcinoma in chronic active hepatitis without cirrhosis. Hepatitis Treatment Study Group.
    Sata M; Ide T; Akiyoshi F; Fukuizumi K; Noguchi S; Shirachi M; Sasaki M; Uchimura Y; Suzuki H; Tanikawa K
    Kurume Med J; 1997; 44(3):171-7. PubMed ID: 9339647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.